EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Treatment Sequencing in Platinum-Resistant Epithelial Ovarian Cancer After MIRASOL, KEYNOTE-B96, and ROSELLA

Yuling Liu, Meng Xu, Jiao Ma, Yu Zhu, Meiling Gao

International Journal of Women's Health · 2026-07 · Volume 18 · 1-17

DOI: 10.2147/ijwh.s624084 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Women's Health, 2026-07. Verfasst von Yuling Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, the First Hospital of China Medical University, Shenyang, 110001, People's Republic of China. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Platinum-resistant epithelial ovarian cancer has long been managed as a clinically defined state with limited therapeutic differentiation. This narrative review aims to clarify how recent Phase III evidence should inform treatment allocation and sequencing after the MIRASOL, KEYNOTE-B96, and ROSELLA trials. Historically, treatment relied on non-platinum single-agent chemotherapy, with bevacizumab added for selected patients after AURELIA; however, this approach did not overcome short progression-free survival, limited response durability, cumulative toxicity, and the absence of robust biological selection. Recent randomized evidence has changed this landscape. MIRASOL established mirvetuximab soravtansine as a folate receptor alpha (FRα)-directed antibody-drug conjugate (ADC) for assay-defined FRα-positive platinum-resistant disease. KEYNOTE-B96 showed that pembrolizumab added to weekly paclitaxel, with or without bevacizumab, improves outcomes in programmed death ligand 1 (PD-L1) combined positive score (CPS)-positive platinum-resistant recurrent epithelial ovarian cancer. ROSELLA demonstrated that relacorilant, a selective glucocorticoid receptor (GR) antagonist, improves the activity of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in a population selected by clinical criteria rather than by a conventional tumor biomarker. Together, these trials define three distinct evidence anchors: FRα-targeted ADC therapy, PD-L1 CPS-selected chemoimmunotherapy, and tumor-biomarker-independent GR antagonism with nab-paclitaxel. They do not establish a simple hierarchy of preferred regimens. Instead, treatment sequencing should integrate biomarker eligibility, prior bevacizumab and poly (ADP-ribose) polymerase inhibitor exposure, taxane feasibility, ocular and immune-related toxicity risks, corticosteroid requirements, disease tempo, and patient priorities. The central challenge is to convert these validated options into rational, patient-specific sequencing strategies across biomarker-directed and tumor-biomarker-independent treatments. Patients with ovarian, fallopian tube, or primary peritoneal cancer that no longer responds well to platinum chemotherapy have historically had limited treatment options. Standard non-platinum chemotherapy and bevacizumab can still help some patients, but recent trials have introduced more specific ways to choose treatment. MIRASOL supports mirvetuximab soravtansine for patients whose tumors have high folate receptor alpha expression. KEYNOTE-B96 supports pembrolizumab with weekly paclitaxel, with or without bevacizumab, for patients whose tumors meet a programmed death ligand 1 testing threshold. ROSELLA supports relacorilant with nab-paclitaxel for selected patients without requiring a tumor biomarker test. These options do not create one fixed best order for all patients. Instead, clinicians need to consider tumor test results, prior treatments, whether taxane treatment is suitable, eye and immune-related side effects, need for corticosteroids, pace of disease, and patient preferences. This review summarizes how these trial results can be used to guide treatment selection and sequencing in routine care.

Schlagwörter

Stichwörter der Autor:innen

antibody-drug conjugatefolate receptor alphaglucocorticoid receptormirvetuximab soravtansinepembrolizumabplatinum-resistant ovarian cancerrelacorilanttreatment sequencing

Autor:innen und Institutionen

  • Department of Gynecology, the First Hospital of China Medical University, Shenyang, 110001, People's Republic of China.
  • Department of Obstetrics, the First Hospital of China Medical University, Shenyang, 110001, People's Republic of China.

Zitieren

APA

Liu, Y., Xu, M., Ma, J., Zhu, Y., & Gao, M. (2026). Treatment Sequencing in Platinum-Resistant Epithelial Ovarian Cancer After MIRASOL, KEYNOTE-B96, and ROSELLA. International Journal of Women's Health, Volume 18, 1-17. https://doi.org/10.2147/ijwh.s624084

Vancouver

Liu Y, Xu M, Ma J, Zhu Y, Gao M. Treatment Sequencing in Platinum-Resistant Epithelial Ovarian Cancer After MIRASOL, KEYNOTE-B96, and ROSELLA. International Journal of Women's Health. 2026;Volume 18:1-17. doi:10.2147/ijwh.s624084

BibTeX
@article{Liu2026,
  author = {Liu, Yuling and Xu, Meng and Ma, Jiao and Zhu, Yu and Gao, Meiling},
  title = {Treatment Sequencing in Platinum-Resistant Epithelial Ovarian Cancer After MIRASOL, KEYNOTE-B96, and ROSELLA},
  journal = {International Journal of Women's Health},
  year = {2026},
  volume = {Volume 18},
  pages = {1--17},
  doi = {10.2147/ijwh.s624084}
}
Kostenlos starten →